Takeda is walking away from orteronel, its most advanced oncology candidate, after the prostate cancer treatment failed to significantly improve overall survival in two studies, a setback for the company’s in-transition Millennium unit.

…read more

Source: Takeda dumps its top cancer contender after a late-stage struggle


0 No comments